MicroRNA‐542‐3p inhibits tumour angiogenesis by targeting Angiopoietin‐2

Angiopoietin‐2 (Angpt2) plays a critical role in angiogenesis and tumour progression. Therapeutic targeting of Angpt2 has been implicated as a promising strategy for cancer treatment. Whereas miRNAs are emerging as important modulators of angiogenesis, regulation of Angpt2 by miRNAs has not been established. Here we firstly report that Ang2 is targeted by a microRNA, miRNA‐542‐3p, which inhibits tumour progression by impairing Ang2's pro‐angiogenic activity. In cultured endothelial cells, miR‐542‐3p inhibited translation of Angpt2 mRNA by binding to its 3′ UTR, and addition of miR‐542‐3p to cultured endothelial cells attenuated angiogenesis. Administration of miR‐542‐3p to tumour‐bearing mice reduced tumour growth, angiogenesis and metastasis. Furthermore, the level of miR‐542‐3p in primary breast carcinomas correlated inversely with clinical progression in primary tumour samples from stage III and IV patients. Together, these findings uncover a novel regulatory pathway whereby an anti‐angiogenic miR‐542‐3p directly targets the key angiogenesis‐promoting protein Angpt2, suggesting that miR‐542‐3p may represent a promising target for anti‐angiogenic therapy and a potential marker for monitoring disease progression. Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd

[1]  B. Naumnik,et al.  Angiogenic axis angiopoietin-1 and angiopoietin-2/Tie-2 in non-small cell lung cancer: a bronchoalveolar lavage and serum study. , 2013, Advances in experimental medicine and biology.

[2]  R. Hui,et al.  Single chain Fv antibody against angiopoietin-2 inhibits VEGF-induced endothelial cell proliferation and migration in vitro. , 2003, Biochemical and biophysical research communications.

[3]  G. Christofori,et al.  Angiopoietin-1 and -2 exert antagonistic functions in tumor angiogenesis, yet both induce lymphangiogenesis. , 2011, Cancer research.

[4]  W. Filipowicz,et al.  Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? , 2008, Nature Reviews Genetics.

[5]  Abhijit Bhat,et al.  Targeting the ANGPT–TIE2 pathway in malignancy , 2010, Nature Reviews Cancer.

[6]  A. Blann,et al.  Plasma angiopoietin‐1, angiopoietin‐2 and Tie‐2 in breast and prostate cancer: a comparison with VEGF and Flt‐1 , 2003, European journal of clinical investigation.

[7]  T. Berg,et al.  Angiopoietin-2 Serum Levels Are Elevated in Patients With Liver Cirrhosis and Hepatocellular Carcinoma , 2007, The American Journal of Gastroenterology.

[8]  Hubing Shi,et al.  Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis. , 2009, Cancer research.

[9]  D. Nam,et al.  Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. , 2010, Cancer cell.

[10]  K. Lee,et al.  Serum angiopoietin-2 as a clinical marker for lung cancer. , 2007, Chest.

[11]  R. D'Amato,et al.  Angiogenesis inhibition in age-related macular degeneration. , 1995, Ophthalmology.

[12]  C. Lewis,et al.  Expression of Tie-2 by Human Monocytes and Their Responses to Angiopoietin-21 , 2007, The Journal of Immunology.

[13]  I. Majsterek,et al.  Angiogenesis Markers Quantification in Breast Cancer and Their Correlation with Clinicopathological Prognostic Variables , 2011, Pathology & Oncology Research.

[14]  L. Naldini,et al.  Angiopoietin-2 TIEs Up Macrophages in Tumor Angiogenesis , 2011, Clinical Cancer Research.

[15]  T. Kodama,et al.  The calcineurin-NFAT-angiopoietin-2 signaling axis in lung endothelium is critical for the establishment of lung metastases. , 2013, Cell reports.

[16]  K. Alitalo,et al.  Effects of Angiopoietin-2-Blocking Antibody on Endothelial Cell–Cell Junctions and Lung Metastasis , 2012, Journal of the National Cancer Institute.

[17]  P. Campochiaro,et al.  Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. , 2002, Developmental cell.

[18]  Yan Fu,et al.  NFAT1 Mediates Placental Growth Factor-Induced Myelomonocytic Cell Recruitment via the Induction of TNF-α , 2010, The Journal of Immunology.

[19]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[20]  D. Schadendorf,et al.  Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma , 2009, Clinical Cancer Research.

[21]  D. Srivastava,et al.  MicroRNAs: Opening a New Vein in Angiogenesis Research , 2009, Science Signaling.

[22]  Evelyn Wenkel,et al.  Circulating Micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection , 2012, PloS one.

[23]  Hubing Shi,et al.  Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin. , 2007, Blood.

[24]  Thomas Korff,et al.  Integration of Endothelial Cells in Multicellular Spheroids Prevents Apoptosis and Induces Differentiation , 1998, The Journal of cell biology.

[25]  L. Naldini,et al.  Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. , 2011, Cancer cell.

[26]  D. Cheresh,et al.  Tumor angiogenesis: molecular pathways and therapeutic targets , 2011, Nature Medicine.

[27]  R. Bañares,et al.  Serum angiopoietin-2 level as a predictor of tumor invasiveness in patients with hepatocellular carcinoma , 2013, Scandinavian journal of gastroenterology.

[28]  Suman Lee,et al.  Induction of growth arrest by miR‐542‐3p that targets survivin , 2010, FEBS letters.

[29]  K. Gunsalus,et al.  Combinatorial microRNA target predictions , 2005, Nature Genetics.

[30]  K. Alitalo,et al.  How do angiopoietins Tie in with vascular endothelial growth factors? , 2010, Current opinion in hematology.

[31]  C. Burge,et al.  Most mammalian mRNAs are conserved targets of microRNAs. , 2008, Genome research.

[32]  Hubing Shi,et al.  Overexpression of platelet-derived growth factor-BB increases tumor pericyte content via stromal-derived factor-1alpha/CXCR4 axis. , 2009, Cancer research.

[33]  Yingbo He,et al.  Soluble tissue factor has unique angiogenic activities that selectively promote migration and differentiation but not proliferation of endothelial cells. , 2008, Biochemical and biophysical research communications.

[34]  Rakesh K. Jain,et al.  Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases , 2011, Nature Reviews Drug Discovery.

[35]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[36]  Doron Betel,et al.  The microRNA.org resource: targets and expression , 2007, Nucleic Acids Res..

[37]  Hubing Shi,et al.  The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin. , 2006, Blood.

[38]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[39]  M. Monden,et al.  Hypoxia-induced up-regulation of angiopoietin-2 in colorectal cancer. , 2006, Oncology reports.

[40]  Gavin Thurston,et al.  Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system , 2009, Nature Reviews Molecular Cell Biology.

[41]  Hongtao Li,et al.  Influence of Pseudomonas aeruginosa quorum sensing signal molecule N-(3-oxododecanoyl) homoserine lactone on mast cells , 2009, Medical Microbiology and Immunology.

[42]  J. Folkman,et al.  Is angiogenesis an organizing principle in biology and medicine? , 2007, Journal of pediatric surgery.